Candel Therapeutics (CADL) Return on Sales (2020 - 2022)

Candel Therapeutics' Return on Sales history runs 3 years deep, the most recent figure standing at 2.54% for Q4 2022.

• In Q4 2022, Return on Sales rose 1038.0% year-over-year to 2.54%; the TTM figure through Dec 2022 stood at 2.84% (down 24.0% YoY), while the FY2022 annual figure was 2.82%, down 24.0% from the prior year.
• Return on Sales came in at 2.54% for Q4 2022 at Candel Therapeutics, up from 2.92% in the prior quarter.
• In the past five years, Return on Sales ranged from a high of 0.81% in Q2 2020 to a low of 12.92% in Q4 2021.
• A 3-year average of 3.07% and a median of 2.54% in 2022 frame the typical range for Return on Sales.
• Across the five-year window, Return on Sales sank 1096 bps in 2021 and soared 1038 bps in 2022, its largest moves.
• Candel Therapeutics' Return on Sales stood at 1.96% in 2020, then sank by 559 bps to 12.92% in 2021, then surged by 80 bps to 2.54% in 2022.
• According to Business Quant data, Return on Sales over the past three periods registered 2.54%, 2.92%, and 2.94% for Q4 2022, Q3 2022, and Q2 2022 respectively.

Peer Comparison